The Authority stated in its opinion of 31 January 2023 [EFSA Journal 2023;21(3):7863.] that, based on the available in vitro chromosomal aberration test and the results of the in vivo micronucleus test, the potential aneugenic activity of robenidine hydrochloride could not be excluded, and that no information on the potential aneugenicity of robenidine hydrochloride was made available in the application. In the absence of such data, the Authority indicated that it could not conclude on the safety of the preparation of robenidine hydrochloride (Cycostat 66G) for the target species and the consumer. The Authority added that, in the absence of adequate data on the ecotoxicological effects of robenidine hydrochloride on soil, water and sediment, it could also not conclude on the safety of the preparation of robenidine hydrochloride (Cycostat 66G) for the environment. And finally, owing to the lack of sufficient data, the Authority could not conclude that the preparation of robenidine hydrochloride (Cycostat 66G) is still efficacious against recent Eimeria spp. strains in rabbits. It results from the Authority’s opinion of 31 January 2023 that it has not been established that the preparation of robenidine hydrochloride (Cycostat 66G) does not have an adverse effect on animal health, human health or the environment, and that it has not been established that it has a coccidiostatic effect, when used as a feed additive for rabbits for breeding and rabbits for fattening in the additive category ‘coccidiostats and histomonostats’.
Recital 6, Regulation (EU) 2023/2594
In forcesince 21 Nov 2023